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Abstract
Background: Functional dyspepsia (FD) is a prevalent gastric disorder that is difficult to manage due to lack of
satisfactory treatments. Acupuncture has been studied with regard to the rising need for treating FD, but the
mechanism verifying its efficacy has not yet been fully revealed. The aim of this study is to explore the efficacy and
mechanism of acupuncture for FD compared with a sham group.
Methods/design: We describe a proposal for a randomized, assessor-blind, sham-controlled trial with 70 eligible
participants who will be randomly allocated either into an acupuncture or a sham group. Participants in the
acupuncture group will receive 10 sessions of real acupuncture treatment and those in the sham group will
be treated with identical sessions using a Streitberger needle. Functional magnetic resonance imaging
(fMRI) and metabolomics studies will be implemented before and after 4 weeks of treatment to investigate
the mechanism of acupuncture. The primary outcome is a proportion of responders with adequate
symptom relief and the secondary outcomes include the Nepean Dyspepsia Index - Korean version,
Functional Dyspepsia-Related Quality of Life questionnaire, Ways of Coping Questionnaire, Coping
Strategies Questionnaire, perception of bodily sensation questionnaire, State-Trait Anxiety Inventory, and
the Center for Epidemiological Studies - Depression Scale. The outcomes will be evaluated before and
after the treatment.
Discussion: This is the first large-scale trial evaluating the efficacy and mechanism of acupuncture with fMRI
and metabolomic methods. We will compare real acupuncture with the Streitberger sham needle to verify
the specific effect of acupuncture. The results of this trial are expected to be relevant evidences affecting
policy and decision-makers associated with routine healthcare.
Trial registration: ClinicalTrials.gov Identifier: NCT02358486.
Date of Registration: 21 January 2015.
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Background
Functional dyspepsia (FD) is a common gastrointestinal
disorder that is defined as persistent or recurrent
abdominal pain or discomfort centered in the upper
abdomen that occurs in the absence of any structural
lesion [1]. The prevalence of FD varies from 11 % to
29.2 % globally [2], and recently more than 40 % of
patients who visited hospitals in South Korea have been
diagnosed with FD [3]. The conventional treatments for
FD include antisecretory agents, prokinetics, and anti-
depressant agents [4]. However, owing to the unsatisfac-
tory efficacy of these approaches, patients with FD often
turn to alternative and complementary therapies such as
acupuncture [5]. Acupuncture has been used in Asia for
centuries to treat FD. During the past decade, many
clinical and experimental research studies have revealed
that acupuncture reduces gastric symptoms, such as
abdominal distension, epigastric pain, and belching
[6–8]. A recent meta-analysis on acupuncture for FD
reported that there was a lack of robust evidence on
the efficacy and safety of acupuncture, which might
be due to the poor quality of previous studies [9].
The mechanism and efficacy of acupuncture is still
not fully understood, and high-quality studies with a
suitable design for acupuncture are needed.
Positron emission tomography (PET) and functional
magnetic resonance imaging (fMRI) are promising
techniques for exploring the central mechanism of
acupuncture [10]. A recent study indicated that the
regional and distant connectivity of the anterior cingu-
late cortex and thalamus are correlated with the se-
verity of FD [11]. Authentic and sham acupuncture
procedures have relatively different brain responses in
the insula and hypothalamus [12]; therefore, an em-
phasis has recently been placed on differentiating the
brain areas activated during acupuncture.
Metabolomics is defined as the systematic study to
measure the multi-parametric metabolic response of a
living system to pathophysiological stimuli or genetic
modification quantitatively [13, 14]. In contrast to the
reductionism of modern medicine, a metabolomic study
approaches from the viewpoint of a living organism in
systemic way, which corresponds with the traditional
Korean medicine (TKM) theory that focuses on holistic
treatment. In addition, changes in metabolites reflect the
response of the biological system; therefore, metabolo-
mics could provide insights about possible mechanisms
underlying the effects of acupuncture. A recent nuclear
magnetic resonance (NMR)-based metabolomics study
showed the potential biological effect of acupuncture on
FD [15]; however, there are some limitations, and the
scientific evidence is still insufficient.
Considering these features, a randomized, assessor-blind,
sham-controlled clinical trial is planned to investigate the
effect of acupuncture on FD. To analyze the mec-
hanism of acupuncture, fMRI will be used in the study
to identify the differences between the sham and
acupuncture groups and their influence on clinical
outcomes. We will also use 1H NMR-based metabo-
lomics to characterize the difference in the metabolic
profiles of the plasma and the urine of FD patients in




The aims of this study are as follows:
(1)Investigate whether manual acupuncture brings
adequate relief of FD symptoms in comparison with
the sham control group.
(2)Determine the difference of brain activity
between the real and sham acupuncture groups
and the correlation between brain and clinical
outcomes.
(3)Assess any correlation between differences and
changes in the metabolite and clinical outcomes.
Hypothesis
We hypothesized that 10 sessions (4 weeks) of acupunc-
ture treatment will improve FD symptoms, and a mech-
anistic difference will exist between the acupuncture and
the sham control for FD based upon the fMRI and the
metabolomics study.
Design
A randomized, assessor-blind, sham-controlled trial
will be performed at the Kyung Hee University Hos-
pital at Gangdong in Seoul, Korea, beginning in
January 2015. The flow of the entire trial is shown
in Fig. 1.
Ethical considerations
This trial will be carried out along with the protocol
approved by the Institutional Review Board (IRB) of
the Kyung Hee University Hospital at Gangdong
(KHNMCOH 2014-08-002-002), the standards of the
International Committee on Harmonization on Good
Clinical Practice, and the revised version of the
Declaration of Helsinki. The purpose and risks of
the trial will be fully explained to the participants,
who will be required to provide informed consent to
indicate that they agree with the protocol and would
take part in the trial. The participants will be able to
quit at any time during the study period. Any finan-
cial costs incurred due to adverse events related to
the trial will be covered for the participants. This trial
is registered at ClinicalTrials.gov (NCT02358486).
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Inclusion and exclusion criteria
The inclusion and exclusion criteria are based on a
previous study [16].
Inclusion criteria
The inclusion criteria are as follows:
(1) Age between 30 and 49 years.
(2) Meeting the definition of FD and postprandial
distress syndrome (PDS) as a subtype of FD
according to the Rome III criteria [17].
(3) Complaints of a degree of dyspepsia that produces a
score of more than 40 points on the visual analog
scale (VAS; 0, no symptom at all; 100, the most
severe symptom one has ever had).
(4) Answer at least three questions worth more than 2
points on the Gastrointestinal Impact Scale.
(5) Have normal esophagogastroduodenoscopy results
within a year and no evidence of any organic diseases.
(6) Individuals who are not supposed to take any other
treatments associated with FD during the study.
Exclusion criteria
Participants with the following characteristics will be
excluded:
(1) Individuals who have obvious organic diseases such
as reflux esophagitis.
(2) Individuals who have apparent signs of irritable
bowel syndrome.
(3) Individuals who have alarming symptoms (weight
loss, black or tarry stool, or dysphagia).
(4) Individuals who have serious internal organ diseases
(diseases of the heart, lung, liver, or kidney) or
mental illness.
(5) Individuals who have undergone surgery related to
the gastrointestinal tract.
(6) Individuals who are pregnant or breastfeeding.
(7) Individuals who are taking drugs that could affect
the gastrointestinal tract; a minimum wash-out
period of 2 weeks is required before participating in
the trial.
(8) Individuals who are positive for human
immunodeficiency virus infection.
(9) Individuals who have severe problems due to
malabsorption.
(10) Individuals who have difficulties in attending the
trial (for example, due to paralysis, serious mental
illness, dementia, drug addiction, time constraints,
severe disorder of vision or hearing, or illiteracy).
(11) Individuals with other issues that could interfere
with acupuncture treatment (for example, clotting
disorders or leukopenia, a pacemaker, epilepsy, or
anticoagulant therapy).
(12) Individuals who have metal implants or fragments
that might influence the fMRI examination.
Recruitment
Banner advertisements will be placed on the notice
boards in the hospital. We will run classified advertise-
ments on web sites that patients with digestive problems
often visit. We will place the advertisements in the local
newspaper and at the bus and subway stations.
Randomization, allocation concealment, and blinding
The randomization will be carried out using random
number lists created in accordance with the PROC
PLAN of SAS 9.2 (SAS Institute Inc., Cary, NC, USA) by
an independent statistician (IY). The allocation list will
be handled by an independent researcher, who will
provide random numbers to the investigator at the
hospital via email. A random number will be assigned
sequentially when the participants pass the screening
test. Investigators who have contact with the participants
should be unaware of the random allocation. Partici-
pants and assessors will be blinded as to which group
they are assigned; however, practitioners involved in the
study will not be blinded. The allocation and feedback
emails will be saved, and the unblinding procedure will
be documented and stored in the trial master file. The
success of the blinding will be evaluated after the
completion of the trial.
Intervention
Detailed information regarding the acupuncture treat-
ment is described in the form of the revised STandards
Fig. 1 Flow of the study
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for Reporting Interventions in Clinical Trials of Acu-
puncture (STRICTA) [18] listed in Table 1. Thirteen
acupoints that are widely used to manage digestive
symptoms are selected [19, 20]. The treatment will last
for 20 minutes each visit, and a total of ten treatment
session will be implemented, including two sessions
during the MRI scanning.
fMRI scanning procedure
fMRI data will be acquired using a 3 T Philips Achieva
MRI scanner (Philips Medical System, Best, the
Netherlands) equipped for echo planar imaging with an
8-channel head coil. A whole-brain T2*-weighted
gradient echo blood oxygenation level-dependent
(BOLD) pulse sequence (repetition time [TR]/echo
time [TE] = 2000/35 ms, flip angle = 90°, 34 axial
slices, voxel size = 2.87 × 2.87 × 4 mm3) will be used.
In addition to the fMRI data, we will collect struc-
tural data using a T1-weighted 3D turbo field echo
(TR/TE = 9.9/4.6 ms, flip angle = 8°, voxel size = 1
mm isotropic). Patients will be asked to lay supine
in the scanner while wearing earplugs to attenuate
the gradient noise.
Patients will participate in three sessions on the same
day: a training session, a nutrition drink test session, and
an imaging session. The training session is intended to
familiarize the subjects with the modified pressure
algometer (MA) and the rating procedures. For the
nutrition drink test session, we will induce postprandial
symptoms and determine pressures to produce appropri-
ate abdominal discomfort to be used during the subse-
quent imaging session.
(1) In the training session, we will introduce our
pressure-induced discomfort stimuli and rating
procedures. A series of 14-second pressure
stimuli will be delivered to the epigastric area
using an MA connected to a rapid cuff inflator
system (Hokanson E20, AG101, Bellevue, WA,
USA). This rapid cuff inflation system allows us
to set an accurate pressure within 1 mmHg.
Using this system, the target pressure can be
reached in 2 seconds, and we can deflate the
pressure immediately. Subjects will be asked to
verbally rate their pressure-induced discomfort
using a 0–100 numerical scale, where 0 is labeled
“no discomfort” and 100 is labeled “the worst
discomfort, but not painful.” We will set the
abdominal pressure to target a discomfort intensity
of about 60/100 as “moderate discomfort.” The
pressure required to induce a 60/100 discomfort
intensity (D60) and discomfort symptoms from
the abdominal pressure will be recorded during
the training session.
(2)In the nutrition drinking test session, subjects will
be asked to consume canned drinks in the morning
after an overnight fast. We will use the same
procedures as those described in a previously
reported protocol [21]. Subjects will consume 200
mL of Newcare (Welife, Cheonan, Republic of
Korea), which contains 1 kcal/mL with 20 g of
carbohydrates, 6 g of fat, and 7 g of protein. Subjects
will drink a can every 4 minutes until they reach a
predetermined maximum level of fullness. At
4-minute intervals, the subjects will verbally rate
their overall fullness levels on a range of 0–5 (0: no
fullness, 1: the first sensation of fullness, 2: mild,
3: moderate, 4: severe, and 5: unbearable fullness).
The participants will be instructed to stop drinking
when their fullness reaches a level of 4. The actual
volume of the canned drinks consumed up until
this point is the maximum tolerable volume.
Questionnaires for postprandial symptoms, intensity
of abdominal discomfort, and abdominal pressure
for the D60 will be administered 15 minutes
after participants complete the test. The regained
pressure for D60 at this point will be used
during the imaging session.
(3)In the imaging session, fMRI data will be acquired
for the meal-loaded discomfort resting state run
(REST), continuous pressure stimuli run (CONT),
and block design pressure stimuli run both before
acupuncture (TASK1) and after acupuncture
(TASK2). Following each scan, the subjects will be
asked to verbally rate their discomfort intensity and
fullness level after each run using the same scales (a
0–100 scale for the discomfort intensity, a 0–5 scale
for the fullness level) as previously instructed during
the training and nutrition drinks test sessions.
For runs in both the REST and CONT runs, subjects
will be instructed to relax and lie still with their eyes
open. The REST is a 6-minute run, and subjects with
abdominal discomfort induced by the nutrition drink
test, as described above, will be allowed to rest without
pressure stimuli. The CONT (continuous MA-induced
discomfort state) lasts for 7 minutes, and a constant and
individually tailored pressure (D60) will be delivered to
each subject.
Both TASK1 and TASK2 runs will consist of a block
design with seven 14-second stimulation blocks (ON)
interspersed between eight 30-second rest blocks (OFF).
The total time for the block design run is 5 minutes and
20 seconds. For the stimulation blocks, we will use the
same D60 pressure level, which is predetermined from
the nutrition drinks test session. The subjects will be
instructed to use a button during the TASK runs to indicate
when the pressure-induced discomfort is not decreasing
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Table 1 Acupuncture treatment details based on the STRICTA 2010 checklist
Item Detail
1. Acupuncture rationale 1a) Style of acupuncture
- Manual acupuncture based on traditional meridian theory.
1b) Reasoning for treatment provided, based on historical context, literature sources,
and/or consensus methods, with references where appropriate
- Manual acupuncture treatments based on the traditional meridian theory, clinical experience,
and consensus by the experts in acupuncture and FD.
1c) Extent to which treatment was varied
- No additional acupoints allowed.
2. Details of needling 2a) Number of needle insertions per subject per session (mean and range where relevant)
- Fixed 13 acupoints.
2b) Names (or location if no standard name) of points used (uni/bilateral)
- LI 4, ST36, LR3, PC3, SP4, and ST34 (bilateral) and CV12 (unilateral).
2c) Depth of insertion, based on a specified unit of measurement or on a particular tissue level
- From 5 to 30 mm.
2d) Response sought (for example, de qi or muscle twitch response)
- De qi sensation
2e) Needle stimulation (manual, electrical)
- Manual stimulation: needle rotation with thumb and index fingers at 3 Hz.
2f) Needle retention time
- Fifteen minutes.
2 g) Needle type (diameter, length, and manufacturer or material)
- A sterilized stainless steel needle (0.2 × 40 mm, Dongbang Acupuncture Inc., Ungcheon, Boryeong, Korea).
3. Treatment regimen 3a) Number of treatment sessions
- Ten treatment sessions in both groups including two sessions during fMRI scanning.
3b) Frequency and duration of treatment sessions
- Twice weekly for 4 weeks plus additional two treatments during fMRI scanning
(before and after treatment), 15 minutes for each session.
4. Other components of treatment 4a) Details of other interventions administered to the acupuncture group (moxibustion,
cupping, herbs, exercises, lifestyle advice)
- No other interventions during the study period allowed.
4b) Setting and context of treatment, including instructions to practitioners, and information
and explanations to patients
- Participants will be informed that the acupuncture treatment is based on traditional Korean
medicine and previous studies on clinical trial.
5. Practitioner background 5) Description of participating acupuncturists (qualification or professional affiliation, years in
acupuncture practice, other relevant experience)
- Korean medicine doctors who have license and at least 3 years of experience of treating
gastrointestinal diseases. They have studied acupuncture for more than 10 years and graduated
from a university of Korean medicine. To ensure providing identical treatments, they finished
10 hours of training and simulated the protocol.
6. Control or comparator interventions 6a) Rationale for the control or comparator in the context of the research question, with sources that
justify this choice
- Streitberger needle will be used as a sham control (its rationale is described in background and
discussion of main text).
6b) Precise description of the control or comparator. If sham acupuncture or any other type of
acupuncture-like control is used, provide details as for items 1 through 3 above.
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after the abdominal pressure stimulation ends. Either real
or sham acupuncture will be applied after the TASK1 run,
and 15 minutes of retention time will be given to gain a
sufficient acupuncture effect. The TASK2 run will be
followed by the acupuncture treatment and structural data
collection. The entire imaging session procedure is
summarized in Fig. 2.
fMRI data processing
Functional MRI data will be processed using the FSL
(FMRIB Software Library; http://fsl.fmrib.ox.ac.uk/fsl),
AFNI (Analysis of Functional NeuroImages; https://
afni.nimh.nih.gov/afni), and FreeSurfer (http://freesur-
fer.net) software packages. Data will be corrected for
physiological artifacts, slice timing, and affine head mo-
tion, and non-brain extraction will also be performed.
Cortical surface reconstruction will be carried out to im-
prove structural-functional co-registration using FreeSur-
fer’s bbregister tool, and then the data will be registered to
the standard Montreal Neurological Institute (MNI) space.
Spatial smoothing and temporal filtering will be applied.
We will determine the functional connectivity for the
data from the REST and CONT runs using seed correl-
ation analysis and independent component analysis. For
the seed correlation analysis, seeds will be defined based
on the block design runs results (TASK1 and TASK2)
and other discomfort/visceral stimulation fMRI studies
[22–25]. For the TASK runs, statistical parametric
mapping at the single subject level will be carried out
using a generalized linear model (GLM) with a stimulation
block design and discomfort as the explanatory variables.
In order to investigate the link between discomfort-
induced brain functions and behavioral/clinical measures,
we will perform a whole-brain voxel-wise linear analysis.
All brain maps will be thresholded using a cluster correc-
tion for multiple comparisons at a z score > 2.3 and a
cluster size threshold of p < 0.05.
Outcome measurement
A clinical research coordinator who is also a licensed
nurse will evaluate the outcome variables as an assessor.
He/she is supposed to be unaware of the group to which
the subject is assigned.
Primary outcome
The primary outcome is the proportion of responders
(PR) [26] defined as the proportion of participants who
answer “yes” to more than half of the adequate relief
questions during the treatment period. The adequate
relief question is: After the last visit, have you had
adequate relief of your stomach pain or discomfort?
Table 1 Acupuncture treatment details based on the STRICTA 2010 checklist (Continued)
- Practitioners will use identical acupoints to sham group compared with real acupuncture group.
- The depth of insertion, response sought, needle stimulation, needle retention time, treatment
period, and number of treatment sessions in sham group will be the same as those
in real acupuncture group.
- In sham acupuncture group, Streitberger placebo needles (0.2 × 40 mm, Asia Med GmbH,
Germany) will be used.
STRICTA STandards for Reporting Interventions in Clinical Trials of Acupuncture, FD functional dyspepsia, LI large intestine, ST stomach, LR liver, PC pericardium, SP
spleen, CV conception vessel
Fig. 2 Functional magnetic resonance imaging experiment paradigm (REST, meal-loaded steady-state resting run; CONT, continuous MA
steady-state run; TASKT1/2, block design MA stimulus run; T1, structural image acquisition; ACUP, acupuncture treatment; MA, modified
pressure algometer)
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Secondary outcomes
Nepean Dyspepsia Index - Korean version (NDI-K)
The Nepean Dyspepsia Index (NDI) was developed by
Talley et al. [27] and has been reported as a reliable
questionnaire to measure the severity of dyspeptic symp-
toms and quality of life [28, 29]. The Korean version of
the NDI (NDI-K) was validated by Lee et al. [30]. The
minimum clinically important difference of NDI is 10
points on the total scale [31]. The NDI-K consists of two
categories (symptom-based questions and quality of life);
in this study, we will use only symptom-based questions
about the period, severity, and degree of distress of 15
symptoms at baseline and again after 4 weeks.
Functional Dyspepsia-Related Quality of Life (FD-
QoL) questionnaire The FD-QoL questionnaire is made
up of four sections with a total of 21 questions regarding
quality of life measured by a 5-point Likert scale (0: not
at all or not applicable, 1: a little, 2: moderately, 3: quite
a lot, and 4: extremely). The FD-QoL questionnaire is
distributed into 5 items about diet, 4 items about daily
activity, 6 items regarding emotion, and 6 items about
social functioning. The questionnaire is known to be
reliable and trustworthy for assessing the effect of
dyspepsia on a patient’s overall quality of life [32]. The
FD-QoL questionnaire will be administered at baseline
and again after 4 weeks.
Numeric Rating Scale (NRS) for abdominal discomfort
Subjects will be asked to verbally rate the intensity of
their abdominal discomfort after each MA-induced
discomfort MRI run (CONT, TASK1, and TASK2). We
will use a 0–100 Numeric Rating Scale (NRS), where 0 is
labeled “no discomfort” and 100 is labeled “the most
intense discomfort tolerable”.
Ways of Coping Questionnaire (WCQ) We will use
the WCQ, which is composed of 66 items and uses a
4-point Likert scale that was developed by Folkman et al.
[33] and validated by Lundqvist et al. [34]. There are 8
coping strategies: (1) Confrontive coping, (2) Distancing,
(3) Self-controlling, (4) Seeking social support, (5) Accept-
ing responsibility, (6) Escape-avoidance, (7) Planful prob-
lem solving, and (8) Positive reappraisal. In the WCQ,
these 8 areas are categorized into 2 groups (active coping
and passive coping). The WCQ will be administered at
baseline and again after 4 weeks.
Coping Strategies Questionnaire (CSQ) The CSQ is
made up of 48 items and uses a 7-point Likert scale
validated by Franco et al. [35] to evaluate the coping
strategy for pain or acupuncture treatment. The CSQ is
distributed across 8 areas: (1) Catastrophizing, (2) Dis-
tractor behaviors, (3) Self-instructions, (4) Ignoring the
pain, (5) Reinterpreting the pain, (6) Hoping, (7) Faith
and praying, and (8) Cognitive distraction. These areas
are classified as either adaptive coping or disadaptive
coping. The CSQ will be administered at baseline and
after 4 weeks.
Perception of bodily sensation (PBS) We will apply
the PBS questionnaire developed by Schneider et al. [36]
at baseline to assess the response to the abdominal
discomfort induced by MA. The level of perceived bodily
sensation varies from person to person and might lead
to different responses of brain activation. The question-
naire consists of 10 areas and uses a 6-point Likert scale
where higher points indicate a more sensitive response.
In our trial, the PBS plays an important role in analyzing
the brain’s response to abdominal discomfort.
State-Trait Anxiety Inventory (STAI) The STAI [37] is
a questionnaire that evaluates anxiety as a psychological
factor. It consists of 40 items: 20 items to assess the state
of anxiety (anxiety triggered by a specific event), and 20
items to determine the trait of anxiety (anxiety derived
from personal characteristics) according to a 4-point
Likert scale. Higher scores indicate a higher degree of
anxiety. Dyspeptic symptoms and anxiety are closely
correlated [38, 39]. Therefore, the effect of acupuncture
on anxiety will be evaluated. This measurement will be
checked at baseline and again after 4 weeks.
Center for Epidemiological Studies - Depression
Scale (CES-D) The CES-D was developed by Radloff in
1977 and has been applied worldwide [40, 41]. It is both
valid and reliable for assessing self-reported depression.
The CES-D is composed of 20 areas; it uses a 4-point
Likert scale where higher scores indicate more severe
depression. Generally, a total sum score of more than 25
points indicates definite depression; more than 21 points
is probable depression, while more than 16 points is
possible depression. The CES-D will be evaluated at
baseline and after 4 weeks to determine if there was
an association between depression and the effects of
acupuncture treatment.
Metabolomics A metabolomics study will be performed
to analyze the difference between (1) FD before and after
acupuncture treatment and (2) the acupuncture and
sham acupuncture groups. Blood and urine samples will
be collected at baseline and after 4 weeks. After collect-
ing the blood, the plasma will be isolated by centrifuga-
tion and stored in a −73 °C deep freezer. The urine
samples will be inverted two or three times, pipetted
into the cryo tubes, and stored in the deep freezer until
the time of analysis. The sample will be analyzed by
NMR and ultra-performance liquid chromatography
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quadrupole/time of flight mass spectrometry (UPLC-Q/
TOF MS). After obtaining the NMR and MS data for
blood and urine samples, the patterns and bio-
markers for FD could be discovered using a multi-
variate statistical analysis.
Sample size calculation
The sample size was calculated based on a previous
study [42] and the opinions of an expert group. Consid-
ering the previous study and the fact that more than a
30 % difference is regarded as significant in clinical
practice based upon expert opinions, we assume that 70
% of the participants in the acupuncture arm would
achieve adequate relief for over half of the study period,
while up to 35 % of those in the sham group would
achieve such an outcome. We set the dropout ratio at 10
%, the level of significance at α = 0.05, and a power of








pt 1−ptð Þ þ pc 1−pcð Þ
q 2
= pt−pcð Þ2
assuming pt = 0.7 (pt: the effect of the acupuncture
group) and pc = 0.35 (pc: the effect of the sham
control group).
We also considered the recent trend of neuroimaging
trials when calculating sample size. In fMRI studies that
use approximately 90,000 voxels to estimate the BOLD
signal indirectly, conventional power calculations are
often meaningless. Therefore, most related studies deter-
mined less than 20 participants to be an adequate
sample size [22, 43, 44] due to the high cost of fMRI
examinations. Therefore, we have assumed 35 subjects
in each group considering the global trend of increases
in subjects to ensure that we obtain sufficient data for
our analysis.
Statistical analysis
A statistical analysis will be conducted by an independ-
ent statistician using SPSS 16.0 (SPSS Inc., Chicago, IL,
USA). All continuous variables will be presented as
means and SDs, and categorical variables will be shown
as a number (%). All analyses will be based on the
intention-to-treat principle using the last observation
carried forward rule. The statistical significance level will
be considered to be 0.05 (two-sided) with 95 % confidence
intervals (CI). When continuous variables are com-
pared between two groups, a two-sample t-test (paramet-
ric method) or Mann–Whitney U test (non-parametric
method) will be used. The paired t-test (parametric
method) or Wilcoxon signed ranks test (non-paramet-
ric method) will be used to compare continuous vari-
ables both before and after the treatment. When the
variable is categorical, a chi-square test or Fisher’s exact
test will be implemented. If there are statistically signifi-
cant differences between groups, an analysis of covariance
(ANCOVA) or logistic regression will be used.
Metabolomics study analysis
A multivariate statistical analysis will be conducted from
the data obtained from the MS or NMR spectra of
collected blood or urine samples using SIMCA-P version
12.0 (Umetrics, Umeå, Sweden). A principal component
analysis (PCA), partial least squares-discriminant ana-
lysis (PLS-DA), or orthogonal projections to latent
structure-discriminant analysis (OPLS-DA) will be used
to process the data. In addition, to investigate the
variables affecting the differences in metabolites between
the groups, the loading plot, S-plot, or the variable
influence on projection (VIP) value will be used.
Safety
We will conduct the following tests on all participants at
the screening stage to exclude patients with serious or-
ganic lesions: white blood cell, hemoglobin, hematocrit,
platelet, aspartate aminotransferase/alanine aminotrans-
ferase, gamma-glutamyl transpeptidase, blood urea ni-
trogen, creatinine, and erythrocyte sedimentation rate.
Adverse events (AEs) will be thoroughly documented at
each visit, and the time of occurrence, severity, treat-
ment, and progress will be recorded. The principal
investigator will evaluate any associations between AEs
and the trial. If serious AEs occur, they will be reported
to the IRB immediately. Participants will be given notice
of any cautions and possible side effects before the fMRI
examination. If side effects develop because of the
acupuncture treatment, such as skin lesions, subcutane-
ous bruising, bleeding or phlebitis signs, participants will
be treated appropriately at no cost to them.
Quality control
To maintain a consistent high quality of the clinical trial,
the clinical research associate will monitor the study file,
informed consent forms, case report forms, serious AEs,
and data records regularly.
Discussion
This study is planned as a randomized, assessor-blind,
sham-controlled trial on the efficacy of acupuncture treat-
ment of PDS in FD diagnosed using the Rome III criteria
compared with the sham acupuncture group. Our trial is
one of the largest randomized controlled trials to explore
the mechanism of acupuncture for FD using fMRI exam-
ination and metabolomics study. This study is also the
first study to investigate the influence of acupuncture on
abdominal discomfort induced by a meal and the MA
pressure-loading device during MRI scanning.
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The researchers who have conducted previous acu-
puncture studies have invested a great amount of effort
into developing appropriate control groups. Creating
proper control groups in acupuncture trials is crucial,
because blinding for practitioners is virtually impossible.
In order to design an appropriate control, we will have
to consider the three major and commonly accepted
therapeutic effects of acupuncture treatment: point-
specific effect, placebo, and non-specific physiological
effect [45]. Acupuncture trials have focused on finding
evidence that the acupuncture treatment is more than
the accumulated non-specific effects related to simple
needle insertion. However, due to the fact that acup-
uncture is a physical, invasive, and manual procedure,
separating both the specific and non-specific effects of
acupuncture is extremely challenging. To differentiate
specific from non-specific effects, researchers have
focused on non-acupoints as a sham control [9], but
none of the trials have mimicked manual acupuncture in
a real clinical practice or adequately fulfilled the criteria
of being truly inert [46]. Our previous study [16], which
had a similar design as this trial, used the acupuncture
wait-list group as the control group. As a result, the
acupuncture group showed a significantly superior effect
over the wait-list participants after expectation and
patient-doctor augmentation effects were controlled for
to exclude a placebo effect (data not shown). However,
there were limitations, such as the non-specific effects
that simply resulted from the needle’s insertion. To
overcome these issues, we will use Streitberger needles
for the patients in the sham control group. In their
study, Streitberger et al. reported that none of the
volunteers suspected that the needle might not have
penetrated the skin [47]. This type of needle has been
regarded as a reliable sham control in many studies
[48–50] and produced successful blinding even in
Chinese subjects who had prior experience with was
estimated based on the acupuncture [51]. We will use
various methods to increase credibility, such as keeping
the sham needles out of the patients’ direct view and using
12-mm wide Steri-strip (manufactured by 3 M) and
MRI-compatible needles to fix the needle evenly
inside the foot, including SP4, in the MRI scanner.
The success of these attempts at blinding will be
examined after the trial’s conclusion.
Current neuroscience studies using positron emission
tomography-computed tomography on FD have demon-
strated an association with the cerebral cortex. The
anterior cingulate cortex (ACC), insula, and thalamus/
hypothalamus, which are the key regions of “gut-brain
communication,” might be most closely related to the
severity of FD [52]. A recent report revealed that
acupuncture might affect the activity of somatic and
visceral sensation and therefore modulate the insula,
ACC, and hypothalamus, which are related to the regu-
lation of homeostasis [10]. One previous neuroimaging
study reported a central mechanism of acupuncture
associated with the pain and anxiety regions of the brain
after gastric distension was induced by inserting a
rubber balloon into the subjects’ stomach [53]. However,
the methods of inducing gastric distension were consid-
ered to be inappropriate because they were inconvenient
and invasive, and there was no intervention, such as
acupuncture. Our study is the first neuroimaging study
to focus on the potential central mechanism of real and
non-penetrating sham acupuncture treatments for FD.
We will investigate the associations between the clinical
efficacy of acupuncture and the brain’s response to
determine any differences with those of the sham
acupuncture procedure. Additionally, our study is the
first trial to focus on the methods of inducing abdominal
discomfort experimentally by MA and a meal. As
visceral hypersensitivity is one of the major mechanisms
for PDS [54], we will investigate the central mechanism
of hypersensitivity using fMRI and the mechanism of how
acupuncture reduces MA-induced abdominal discomfort
in both short-term and longitudinal periods.
FD is classified into two subtypes: PDS and epigastric
pain syndrome (EPS). Patients with PDS complain of
bothersome fullness and abdominal discomfort after
meals, while EPS focuses on an epigastric burning sensa-
tion that frequently occurs during fasting [17]. PDS is
considered a more appropriate target subject than EPS
in this trial because meal ingestion can aggravate PDS
symptoms [55], and PDS patients can be more vulner-
able to epigastric pressure due to abdominal hypersensi-
tivity [56]. Another reason to choose PDS as a subject in
this trial is the large proportion of PDS compared with
other subtypes in Korea. Though more EPS patients are
detected than PDS patients in the USA due to the
tendency to overestimate gastroesophageal reflux dis-
eases [57], more than 70 % of FD patients were desig-
nated to the PDS subtypes in Korea [3]. Our previous
study [16] also found a more than 60 % PDS subtype
ratio; therefore, PDS is considered to represent most FD
patients in Korea.
The effect of acupuncture on the hypothalamus and
its influence on the autonomic nervous system [58, 59]
implies a homeostatic feature, which is thought to be
closely related to a TKM perspective and focuses on
systemic and holistic treatment. Therefore, metabolism
studies are gaining attention in the field of acupuncture
trials. One previous study showed the acupuncture effect
of reversing the levels of metabolites affected in FD
patients, such as leucine/isoleucine and lactate, so that
they more closely resemble those of healthy controls
[15]. However, this method had several defects, such as
a small sample size (six subjects per group), the absence
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of a sham control, and only profiling polar metabo-
lites by NMR. In the present study, we planned 35
subjects per group as a comparatively large sample,
and the change and difference of metabolomic profiles will
be investigated by H NMR and MS compared with the
sham group.
Several studies have suggested various coping strat-
egies for FD. Patients with FD have been reported to use
non-discriminative coping strategies [60], and other
studies have identified a problem-focused and emotion-
focused coping style for FD patients [61, 62]. The
importance of investigating patients’ coping style with
FD symptoms is emphasized by the following conditions:
1) a negative appraisal of FD symptoms or anxiety can
be a key indicator that differentiates the FD and the nor-
mal group [63], 2) the anxiety of FD patients is closely
related to the brain’s response to pain [53], and psycho-
logical coping can be a good clinical treatment method
for FD [64, 65]. Our trial will investigate the influence of
coping mechanisms for acupuncture on its treatment
effect for FD.
A potential limitation of our study is its small sample
size, and this problem will be the focus of future study.
One of the main features of our study is that we will
investigate central and molecular biological mecha-
nisms simultaneously; therefore, we expect our findings
to provide a glimpse of the true mechanism behind
acupuncture for FD.
Trial status
Participant recruitment is currently ongoing.
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